Floatz logo

mis416

Secondary Progressive Multiple Sclerosis

Innate ImmunotherapeuticsUNKNOWNPhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Secondary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Siponimod
Novartis Pharmaceuticals
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
Rituximab
Cairo University
Phase 3BB
bnt162
Novartis Pharmaceuticals
Phase 4BB
Natalizumab
Biogen
Phase 3BB

View all 50 →

Same molecule, other indications

mis416 is also rated in:

primary progressive multiple sclerosisDormant
CCC
Indicative · Phase 1/2
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →